“Zanolimumab (Humax-CD4), a fully human monoclonal antibody with significant clinical responses in cutaneous T-cell lymphoma”, Hematol Meeting Rep, vol. 3, no. 1, Jun. 2009, doi: 10.4081/hmr.v3i1.540.